Urine cytology

DIAGNOSTIC_TEST4 trials

Sponsors

National Cancer Institute (NCI), University of Florence, Mansoura University

Conditions

Bladder CancerUrinary Bladder CancerUrinary Bladder NeoplasmsUrinary Tract CancerUrothelial Carcinoma

Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

CompletedNCT03258593

National Cancer Institute (NCI)Urinary Bladder Neoplasms

Start: 2018-06-07End: 2022-10-17Updated: 2026-08-25

Unknown Phase

Multimodal Spectroscopy to Detect Urothelial Cancer in Urine

University of FlorenceUrinary Bladder Cancer, Urinary Tract Cancer, Urothelial Carcinoma

Start: 2021-01-28End: 2024-01-25Target: 500Updated: 2022-05-09

Can Four Weeks-check Cystoscopy and Urine Cytology After Primary Complete Resection of T1 Bladder Cancer Replace Repeat Biopsy?

Mansoura UniversityBladder Cancer

Start: 2021-12-01End: 2023-01-01Target: 200Updated: 2021-12-22

Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria

CompletedNCT05362539

Mansoura UniversityBladder Cancer

Start: 2019-02-01End: 2022-04-01Updated: 2022-05-05

Related Papers

MP16-20 FINAL RESULTS OF A PHASE I, SINGLE-ARM CLINICAL TRIAL OF THE COMBINATION OF DURVALUMAB AND VICINEUM IN BCG UNRESPONSIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS (NCT03258593)

The Journal of Urology2024-04-153 citations

PD48-09 A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS

The Journal of Urology2024-04-15

PD09-04 INTERIM ANALYSIS OF A PHASE I SINGLE-ARM STUDY OF THE COMBINATION OF DURVALUMAB (MEDI4736) AND VICINIUM (OPORTUZUMAB MONATOX, VB4-845) IN SUBJECTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER PREVIOUSLY TREATED WITH BACILLUS CALMETTE-GUERIN (BCG) (NCT03258593)

The Journal of Urology2021-08-045 citations